mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.064 |
0.06 |
mRNA |
BRD-K30019337 |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
0.06 |
mRNA |
tacedinaline |
CTRPv2 |
pan-cancer |
AAC |
-0.07 |
0.07 |
mRNA |
BRD-K88742110 |
CTRPv2 |
pan-cancer |
AAC |
-0.067 |
0.07 |
mRNA |
BRD-A02303741:carboplatin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.07 |
0.07 |
mRNA |
Nutlin-3 |
CTRPv2 |
pan-cancer |
AAC |
-0.063 |
0.07 |
mRNA |
brivanib |
CTRPv2 |
pan-cancer |
AAC |
0.066 |
0.07 |
mRNA |
PD-0325901 |
CCLE |
pan-cancer |
AAC |
-0.079 |
0.07 |
mRNA |
PD173074 |
GDSC1000 |
pan-cancer |
AAC |
-0.065 |
0.07 |
mRNA |
TW 37 |
GDSC1000 |
pan-cancer |
AAC |
0.061 |
0.07 |